Medical University of South Carolina

Chad Beneker

Campbell McInnes

Ozgur Sahin

Ozge Saatci

Metin Cetin

Abdol-Hossein Rezaeian

Described herein are novel compounds that block the activity of LOX family members having good IC50 values, no cellular toxicity below 10 &#x3bc;M, induce sensitization of the cells to doxorubicin, strong activity in a recombinant LOX/LOXL2 activity, and a chemical structure that is drug-like and does not have a PAINS flag, as well as, methods of treatment using the compounds with respect to cancer, organ fibrosis, neurodegenerative and cardiovascular diseases.

Inhibitors of lysyl oxidases

Herein are described peptide-based compositions for modifying Raf kinase protein Dimerization. These compositions, treatments, and methods of use are directed to peptides that display a binding affinity for the dimer interface of a Raf kinase protein, methods for modifying Raf kinase dimerization, and methods for inhibiting tumor growth. An embodiment of the disclosure is a peptide generated by modifying an ordered sequence chosen from SEQ ID NO: 1 which corresponds to amino acids 503-521 of B-Raf kinase. The peptides disclosed herein include a modification to an ordered sequence of amino acids derived from SEQ ID NO: 1 that can improve or otherwise alter binding affinity of the peptide to the dimer interface.

Growing community of inventors

Columbia, SC, United States of America

Chad Beneker